A Facebook post from a self-described endocrinologist weighing the two drugs for diabetes and obesity. Generic explainer with little new detail.
Recap by typeshit. Post by Facebook on Facebook.
Popular Mechanics traces how her 1980s work at Mass General showed GLP-1 triggers insulin release. Gallup now puts GLP-1 weight loss use at about 11% of Americans.
Barzilai highlights trial results on retatrutide in adults with sleep apnea and obesity or overweight, a new use being tested for Lilly's drug.
The Washington meeting runs November 14 to 17, with primary REDEFINE 9 results and pediatric semaglutide research for kids 6 to under 12.
Researchers tracked spending on drinks while out and found a sharp drop among people taking GLP-1 medications.
A link to the FDA's list of bulk drug substances it says may carry significant safety risks in compounding, relevant to the peptide policy fight.
The analysis weighs whether Viking can become the third company, after Lilly and Novo Nordisk, to win approval for a GLP-1 weight loss drug.
Loading…